Literature DB >> 23040796

Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening.

Tessel Rigter1, Stephanie S Weinreich, Carla G van El, Juna M de Vries, Carin M van Gelder, Deniz Güngör, Arnold J J Reuser, Marloes L C Hagemans, Martina C Cornel, Ans T van der Ploeg.   

Abstract

Since the introduction of enzyme replacement therapy for Pompe disease, awareness and early diagnosis have gained importance. Because the therapy is most effective when started early and methods for dried bloodspot screening for Pompe disease are currently being explored, neonatal screening is getting increased attention. The objective of this study was to investigate the gains that might be achieved with earlier diagnosis by neonatal screening. For this purpose we analyzed the health and functional status of non-screened patients with Pompe disease at the time of diagnosis. Previously collected clinical data and results of an international patient-reported questionnaire were used. Cross-sectional data of 53 patients with Pompe disease diagnosed between 1999 and 2009 (aged 0-64 years) were analyzed. According to the World Health Organization's International Classification of Functioning, Disability and Health the following domains are described: body function, activity, participation and contextual factors. In all patients with classic infantile Pompe disease cardiac function, hearing, muscle strength and motor development were considerably impaired at the time of clinical diagnosis. The use of oxygen and/or nasogastric tube-feeding was reported in more than 70% of these cases. Most children, adolescents and adults had advanced muscle weakness and impaired respiratory function at the time of their diagnosis, causing varying degrees of handicap. About 12% of them used a walking device and/or respiratory support at the time of diagnosis. The severely impaired health status reported here provides a strong argument for earlier diagnosis and to further explore the potential of neonatal screening for Pompe disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23040796     DOI: 10.1016/j.ymgme.2012.09.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.

Authors:  J C van der Meijden; D Güngör; M E Kruijshaar; A D J Muir; H A Broekgaarden; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

2.  New targets for monitoring and therapy in Barth syndrome.

Authors:  W Reid Thompson; Brittany DeCroes; Rebecca McClellan; Jessica Rubens; Frédéric M Vaz; Kara Kristaponis; Dimitrios Avramopoulos; Hilary J Vernon
Journal:  Genet Med       Date:  2016-02-04       Impact factor: 8.822

3.  Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

Authors:  Suhrad G Banugaria; Sean N Prater; Trusha T Patel; Stephanie M Dearmey; Christie Milleson; Kathryn B Sheets; Deeksha S Bali; Catherine W Rehder; Julian A J Raiman; Raymond A Wang; Francois Labarthe; Joel Charrow; Paul Harmatz; Pranesh Chakraborty; Amy S Rosenberg; Priya S Kishnani
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

4.  Newborn screening for pompe disease? a qualitative study exploring professional views.

Authors:  Carla G van El; Tessel Rigter; Arnold J J Reuser; Ans T van der Ploeg; Stephanie S Weinreich; Martina C Cornel
Journal:  BMC Pediatr       Date:  2014-08-14       Impact factor: 2.125

Review 5.  Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective.

Authors:  Raymond Saich; Renee Brown; Maddy Collicoat; Catherine Jenner; Jenna Primmer; Beverley Clancy; Tarryn Holland; Steven Krinks
Journal:  Int J Neonatal Screen       Date:  2020-01-09

6.  Hypertransaminasemia and fatal lung disease: a case report.

Authors:  Francesca Santamaria; Sara De Stefano; Silvia Montella; Marco Maglione; Roberto Della Casa; Emma Acampora; Claudio Pignata; Mariacarolina Salerno; Giancarlo Parenti
Journal:  Ital J Pediatr       Date:  2013-02-07       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.